Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Article full text
The full text of this article can be found here.
Disclosures
Maximilian
J. Hochmair has received honoraria from AstraZeneca, Bristol-Myers Squibb,
Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche and had consulting
or advisory roles with Boehringer Ingelheim, Merck Sharp & Dohme, Novartis
and Roche. Anna Buder has received honoraria from AstraZeneca. Helmut Prosch
has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers
Squibb, Merck Sharp & Dohme, Novartis, and Roche, and has received a
research grant from Boehringer Ingelheim. Wolfgang Hilbe has received advisory
board and lecture fees from Boehringer Ingelheim. Agnieszka Cseh and Richard
Fritz are employees of Boehringer Ingelheim. Martin Filipits has received
honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp &
Dohme, Novartis, Ratiopharm, and Roche. Sophia Schwab, and Otto C. Burghuber
have no conflicts of interest to declare.
Funding
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Katharine Williams of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the development of this manuscript.
Copyright
This video is distributed under the terms of the Creative Commons Attribution Noncommerical Licence which permits any noncommerical use, distribution, and reproduction in any medium, provided the original author(s) and the source is credited.
Article full text
The full text of this article can be found here.